- February 20, 2012
N30 Pharma Names Evan Loh, MD and John R. Moore to Board of Directors
Boulder, Colo., February 21, 2012 --N30 Pharmaceuticals, LLC today announced the addition of two new outside director members to its Board of Directors, Dr. Evan Loh and Mr. John Moore. More...PDF(38Kb) - November 11, 2011
N30 Announces Presentation at the CCFA Fall 2011 Conference
Boulder, Colo, November 10, 2011 -N30 Pharmaceuticals, LLC (N30 Pharma) today announced that it would present a poster at the CCFA Inflammatory Bowel Diseases 2011 conference in Florida starting December 1, 2011. The title of the poster is "S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis". More...PDF(787Kb) - August 28, 2011
N30 Announces Presentation at the ACS Fall 2011 National Meeting
Boulder, Colo, August 28, 2011 -N30 Pharmaceuticals, LLC (N30 Pharma) today announced that it would present a poster at the ACS Fall 2011 National Meeting in Denver, CO starting the week of August 28, 2011. The title of the poster is "Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification". More...PDF(471Kb) - July 14, 2011
N30 Announces Poster Presentation at GRC Summer 2011
Boulder, Colo, July 7, 2011 -N30 Pharmaceuticals, LLC (N30 Pharma) today announced that it would make a presentation at the Gordon Research Conference in July 2011. The poster title is "Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis". More...PDF(261Kb) - May 3, 2011
N30 Announces Poster Presentation at ATS 2011
Boulder, Colo, May 3, 2011 -N30 Pharmaceuticals, LLC (N30 Pharma) today announced a presentation at the ATS conference in May 2011. The poster title is "Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation and Decrease Airspace Enlargement in Experimental Models of COPD". More...PDF(503Kb)
…